2. Academic Validation
  3. ML264: An Antitumor Agent that Potently and Selectively Inhibits Krüppel-like Factor Five (KLF5) Expression: A Probe for Studying Colon Cancer Development and Progression

ML264: An Antitumor Agent that Potently and Selectively Inhibits Krüppel-like Factor Five (KLF5) Expression: A Probe for Studying Colon Cancer Development and Progression

Agnieszka Bialkowska 1,  Melissa Crisp 2,  Franck Madoux 2,  Tim Spicer 2,  Ania Knapinska 2,  Becky Mercer 2,  Thomas D. Bannister 3,  Yuanjun He 3,  Sarwat Chowdhury 3,  Michael Cameron 4,  Vincent W. Yang 1,  Peter Hodder 2 4
Affiliations

Affiliations

  • 1 Emory University (current affiliation Stony Brook University School of Medicine)
  • 2 The Scripps Research Institute, Lead Identification Division, Jupiter, FL
  • 3 The Scripps Research Institute, Department of Chemistry, Jupiter, FL
  • 4 Department of Molecular Therapeutics, Jupiter, FL
PMID: 23762940
Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-19994
    99.21%, KLF5 Inhibitor
    KLF